Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14095609 | 0.88 | KMT2A (0.97) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1337663 | 0.88 | KMT2A (0.97) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2306313 | 0.85 | SMN1; SMN2 (0.70) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4285600 | 0.85 | SMN1; SMN2 (0.62) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL953680 | 0.84 | PRSS1 (0.67) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1318178 | 0.84 | MEN1 (0.66) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4281745 | 0.84 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL26025029 | 0.83 | SMN1; SMN2 (0.67) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL9691141 | 0.83 | SMN1; SMN2 (0.67) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL31323430 | 0.83 | KMT2A (0.86) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3063148-A1 | AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| WO-2015063011-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015063011-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB2, PRKAB1 | MEN1 3391/4885KMT2A 1372/4885NPSR1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.